Burlington Newswire

Comprehensive Real-Time News Feed for Burlington, MA.

Results 1 - 10 of 10 for "u:biospace.com" in Burlington, MA

  1. 6 Promising Biopharmas With Major Catalysts in 2018Read the original story w/Photo

    Sunday Jan 28 | BioSpace

    Not only is the biopharma market expected to be a hot one for mergers and acquisitions this year, but it's expected to be hot for stocks as well. It's been big for M&A already, with Celgene acquiring Juno Therapeutics , and Sanofi acquiring Bioverativ and Ablynx .

    Comment?

  2. Massachusetts Upstart scPharmaceuticals Files for $100M IPORead the original story w/Photo

    Oct 23, 2017 | BioSpace

    The Burlington, MA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol SCPH . scPharmaceuticals filed confidentially on August 31, 2017.

    Comment?

  3. Blue Earth Diagnostics??? Initial Results From FALCON Trial Show 61%...Read the original story

    Sep 25, 2017 | BioSpace

    Blue Earth Diagnostics ' Initial Results From FALCON Trial Show 61% Of Patients With Suspected Recurrent Prostate Cancer Had Treatment Plan Changed Following Fluciclovine PET/CT Scan - Results presented at 2017 ASTRO Annual Meeting evaluate clinical utility of fluciclovine PET/CT imaging in men with recurrent prostate cancer following prior treatment - BURLINGTON, Mass. & OXFORD, England-- --Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced the results of a pre-planned interim analysis from an investigational clinical trial evaluating the impact of fluciclovine PET/CT imaging on the clinical management of men with biochemically recurrent prostate cancer eligible for salvage therapy.

    Comment?

  4. Blue Earth Diagnostics Announces Late-Breaking Initial Results Of...Read the original story

    Sep 5, 2017 | BioSpace

    Blue Earth Diagnostics Announces Late-Breaking Initial Results Of Fluciclovine PET/CT Impact On Clinical Management Of Recurrent Prostate Cancer At Upcoming ASTRO Annual Meeting BURLINGTON, Mass. & OXFORD, England-- --Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced the upcoming oral presentation of initial results from the FALCON clinical trial of fluciclovine PET/CT, evaluating its impact on patient management in biochemically recurrent prostate cancer patients scheduled for salvage treatment with curative intent.

    Comment?

  5. MilliporeSigma Release: Call For Entries: $10,000 Award Prize For...Read the original story

    Jun 26, 2017 | BioSpace

    MilliporeSigma is inviting graduate students and recent graduates to enter research projects for a chance to win the $10,000 Life Science Awards Program grand prize in one of three areas: food and beverage safety, 3D printing, and bioseparations. The awards program has been extended from previous years to include additional business sectors and geographies.

    Comment?

  6. Blue Earth Diagnostics Announces Fluciclovine F 18 Presentations At Upcoming (SNMMI) Annual MeetingRead the original story

    Jun 5, 2017 | BioSpace

    BURLINGTON, Mass. & OXFORD, England-- --Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced that several presentations related to fluciclovine F 18 injection will be occurring at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting , from June 10-14, 2017 in Denver, Colo.

    Comment?

  7. Blue Earth Diagnostics??? FALCON Trial Of Fluciclovine (18F) PET/CT...Read the original story

    May 11, 2017 | BioSpace

    Blue Earth Diagnostics ' FALCON Trial Of Fluciclovine PET/CT Imaging In Recurrent Prostate Cancer Stops Recruitment After Successful Interim Analysis OXFORD, England & BURLINGTON, Mass.-- --Blue Earth Diagnostics, a molecular imaging diagnostics company, announced that the Trial Steering Committee recommended that further recruitment be stopped in the FALCON clinical study of fluciclovine PET/CT imaging, based on successful results of a pre-planned interim analysis. The FALCON trial, announced in March 2016, is a UK-based, open-label study to evaluate the clinical impact of fluciclovine PET/CT imaging on patient management decisions in men with biochemically recurrent prostate cancer.

    Comment?

  8. Flexion Reports First Quarter 2017 Financial Results And Recent Business HighlightsRead the original story

    May 4, 2017 | BioSpace

    BURLINGTON, Mass., May 04, 2017 -- Flexion Therapeutics, Inc. today reported financial results for the quarter ended March 31, 2017. "The first few months of 2017 marked another period of impressive growth for Flexion," commented Michael Clayman, M.D., President and Chief Executive Officer.

    Comment?

  9. Blue Earth Diagnostics Announces Publication Of Reader Training Study ...Read the original story

    May 2, 2017 | BioSpace

    Blue Earth Diagnostics Announces Publication Of Reader Training Study Results For Axumin PET Imaging Of Men With Recurrent Prostate Cancer OXFORD, England & BURLINGTON, Mass.-- --Blue Earth Diagnostics, a molecular imaging diagnostics company, announced the peer-reviewed publication of results from the reader training component of Axumin Phase 3 registration data that evaluated the impact of reader training on the blinded, independent evaluation of Axumin images. Axumin is a novel, FDA-approved molecular imaging agent indicated for use in positron emission tomography imaging in men with suspected prostate cancer recurrence based on elevated blood levels of prostate specific antigen following prior treatment.

    Comment?

  10. Massachusetts' Avedro Banks $42 Million, Opens New Facility and Will Continue to Expand Its TeamRead the original story

    Apr 26, 2017 | BioSpace

    Avedro, Inc., an ophthalmic pharmaceutical and medical device company and world leader in corneal remodeling, today announced that it secured a combined $42 million in equity and debt financing. The equity financing was led by HealthQuest Capital, with strong support from existing investors OrbiMed Advisors and InterWest Partners.

    Comment?

Burlington Job Listings
View or post Burlington job listings on Topix.
Burlington Real Estate
News, listings, and foreclosures in Burlington from Topix.
Burlington Mortgages
Find mortgage rates in Burlington on Topix.